Backed by big medtech including Medtronic, MD Start aims not just to incubate start-ups but to create new device companies from scratch.
A new player has entered the liquid biopsy game.
Three years after being merged with QLT the Aegerion business is to be sold out of bankruptcy protection.
Payment of an overdue $120m Astrazeneca milestone, plus two other obligations, has been met through a loan facility with undisclosed terms.
Using EvaluatePharma data, Vantage has described how big pharma R&D spending has shifted, showed how internally discovered novel medicines account for a growing…
In 2018 more than a quarter of medtech funding came from rounds in which corporate VCs took part.
The CAR-T company cancels its Nasdaq IPO after securing more in a Novartis-led private financing.
Biopharma IPOs dipped in the opening months of 2019, but numbers look fairly healthy despite January's US government closure.
The IPO hopeful Cirius Therapeutics presented intriguing Nash data at EASL, but with the final readout from a phase IIb study looming the company’s real value is hard to…